Survey of nearly 700 clinicians across more than 600 surgical facilities in 15 countries showcases need for reduced complexity and interoperability across digital surgery Clinicians expect surgical software to increase patient capacity, improve patient and clinician satisfaction, and reduce care costs

New Drug Application supported by results from the Phase 2b SunRISe-1 study

• 2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* • 2025 Second-Quarter reflects earnings per share (EPS) of $2.29 and adjusted EPS of $2.77 • Significant new product pipeline progress including approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, data for CARVYKTI overall survival and progression-free benefits in multiple myeloma, and continuation of the clinical trial for a general surgery robotic system, OTTAVA • Strong operational performance and favorable foreign exchange results in Company increasing full year estimated reported sales5 guidance at the midpoint by $2 billion dollars to 5.4% and full year EPS guidance by $0.25 to $10.85. Adjusted operational EPS increased to $10.68 at the midpoint.

Accepted abstracts include discussion of novel embolization approach to treating migraine and microcatheter retention risks for liquid embolic agents

New flow rate guidance designed to optimize irrigation and support consistent procedural outcomes 10,000+ VARIPULSE global procedures with low adverse event rate reinforces platform’s strong safety profile

Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA® is FDA approved to treat schizophrenia and is the first and only approved treatment for bipolar I and II depression as an adjunctive and monotherapy With the addition of CAPLYTA® to Johnson & Johnson’s robust portfolio of therapies, the Company now offers the broadest range of treatment options for adults with schizophrenia

The submission is based on results from the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone or prednisolone compared to a current standard of care, abiraterone acetate plus prednisone or prednisolone1 The results demonstrate significant and clinically meaningful benefits of the niraparib and abiraterone acetate plus prednisone or prednisolone regimen in delaying cancer progression and worsening of symptoms1

Open call for innovation to help accelerate promising artificial intelligence (AI) solutions that target pressing challenges in surgery NVIDIA and Amazon Web Services (AWS) will join committee to evaluate and select awardees Effort builds on work within J&J MedTech’s Polyphonic™ Digital Ecosystem to provide AI innovation a path into ORs globally

World’s leading* contact lens brand ACUVUE brings pioneering innovation for astigmatic patients with presbyopia, providing visual clarity and comfort2 Launch reinforces Johnson & Johnson’s position as world leader in contact lenses* – pushing boundaries in optical and material science